Ginkgo Bioworks CFO Steven Coen sells $36,045 in stock

Steven P. Coen, Chief Financial Officer of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), sold shares of the company’s Class A Common Stock on October 5, 2026. The executive disposed of 2,403 shares for a total value of $36,045, with prices received at $15.00 per share.

The shares were sold pursuant to a sales plan adopted by Mr. Coen that is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Notably, the stock currently trades at $11.47, well below the $15.00 transaction price, reflecting the volatile price movements characteristic of DNA shares. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment, placing it among opportunities on the Most Undervalued list.

Following this transaction, Mr. Coen beneficially owns 49,448 shares of Ginkgo Bioworks Holdings, Inc. Class A Common Stock. Investors seeking deeper insights can access a comprehensive Pro Research Report on DNA, one of 1,400+ US equities covered with expert analysis and actionable intelligence.

In other recent news, Ginkgo Bioworks Holdings reported its Q2 2026 financial results, showing a significant revenue decline. The company’s revenue fell to $20 million, falling short of the $29.9 million forecast and marking a 48% decrease from the previous year. Despite this, Ginkgo reported an adjusted loss of $0.92 per share, which was better than the anticipated $1.05 loss. The company remains focused on developing its autonomous labs, including the expanded Nebula system in Boston. Ginkgo ended the quarter with $389 million in total liquidity and reaffirmed its full-year cash burn guidance of $125 million to $150 million.

Analysts have expressed concerns about Ginkgo’s growth trajectory, with TD Cowen downgrading the stock to Hold from Buy and lowering its price target to $9.00 from $12.00, citing the need for continued investment. BTIG also maintained a Sell rating, reducing its price target to $5.00 from $9.00, following discussions with Ginkgo’s leadership. The company is in a transition phase, focusing on building out its Autonomous Labs by 2026, which requires significant capital and time.